STOCK TITAN
  1. Home
  2. News
  3. BIOR

BIORA THERAPEUTICS INC - BIOR STOCK NEWS

Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.

Biora Therapeutics Inc. (BIOR) is a clinical-stage biotechnology company pioneering smart pill-based drug delivery systems for targeted and systemic therapies. This page provides investors and stakeholders with timely updates on the company’s progress in redefining treatment for gastrointestinal diseases and chronic conditions.

Access the latest press releases, clinical trial milestones, and financial reports related to Biora’s innovative platforms—including the NaviCap™ targeted colon release system and BioJet™ needle-free delivery technology. Stay informed about regulatory developments, research collaborations, and strategic partnerships shaping the future of oral biotherapeutics.

This resource is designed for efficient tracking of BIOR’s advancements in drug-device combinations and precision medicine. Bookmark this page or check back regularly for verified updates directly from the company and trusted financial news sources.

News

Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced a new research collaboration with a large pharmaceutical company to test the BioJet Systemic Oral Delivery Platform in animal models. The agreement provides funding to test the platform’s ability to achieve bioavailability through oral delivery of the collaborator’s molecules to the small intestine. The CEO, Adi Mohanty, highlighted the progress and recognition by others, stating that they are actively conducting studies with multiple collaborators and looking forward to performing studies with the big pharma collaborator in the first quarter. Biora's BioJet technology features strong patent protection and promises category-leading oral bioavailability for large molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
none
-
News

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) has received FDA clearance for its Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis. The IND is the first active one for an ingestible drug and device combination. BT-600 utilizes Biora's NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, targeting delivery directly to the colon. The phase 1 trial will evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers receiving BT-600 with tofacitinib at 5 mg and 10 mg doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
clinical trial
-
News

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) provided a corporate update, reporting financial results for the third quarter and announced the advancement of their NaviCap™ Targeted Oral Delivery platform towards a phase 1 clinical trial by year-end. The BioJet™ Systemic Oral Delivery platform also shows potential for liver-targeted delivery of large molecules, with pharma collaborations accelerating. Management will host a conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
earnings
News

Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Rhea-AI Summary
Biora Therapeutics, Inc. will report financial results and provide a corporate update for Q3 2023. The webcast and conference call will be held on November 13, 2023, at 4:30 PM Eastern time. Dial-in and webcast details are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
conferences earnings
-
News

Biora Therapeutics Submits Updated IND Application for BT-600

Rhea-AI Summary
Biora Therapeutics, Inc. has submitted an updated Investigational New Drug (IND) application for BT-600 to the FDA. The update includes additional information and extends the regulatory review period. BT-600 is a drug/device combination using Biora's NaviCap™ ingestible drug delivery device with a liquid formulation of tofacitinib for ulcerative colitis. The phase 1 clinical trial will evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
clinical trial
-
News

Biora Therapeutics to Submit Updated IND Application for BT-600

Rhea-AI Summary
Biora Therapeutics provides an update on its IND application for BT-600, a drug/device combination for the treatment of ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.93%
Tags
clinical trial
News

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Rhea-AI Summary
Biora Therapeutics presents positive data on oral delivery of GLP-1 receptor agonist using BioJet platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
News

Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program

Rhea-AI Summary
Biora Therapeutics submits IND application for BT-600, a drug/device combination for ulcerative colitis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
clinical trial
-
News

Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure

Rhea-AI Summary
Athyrium Capital Management increases equity exposure through convertible notes exchange at a 44% premium to closing price, resulting in $50 million debt reduction. On track to file an IND this month for NaviCap™ BT-600 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
News

Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Biora Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
conferences
Stock BIOR logo
BIORA THERAPEUTICS INC

Nasdaq:BIOR

BIOR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BIOR Stock Data

994.99k
4.52M
0.1%
36%
6.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO